TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid LeukemiaAaron D. Goldberg, Martin S. Tallman, Gail J. Roboz et al.|Blood|2018Cited by 45
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk <i>NPM1</i>-mutated AMLOnyee Chan, Jeffrey E. Lancet, Najla H. Al Ali et al.|Blood Advances|2024Cited by 31
Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid LeukemiaChetasi Talati, Kendra Sweet, Aaron D. Goldberg et al.|Blood|2018Cited by 6
Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk <i>NPM1</i>-Mutated AMLOnyee Chan, Jeffrey E. Lancet, Najla Al Ali et al.|Blood|2022Cited by 2